Type 1 Diabetes (Juvenile Diabetes) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Type 1 Diabetes (Juvenile Diabetes) – Pipeline Review, H2 2017’, provides an overview of the Type 1 Diabetes (Juvenile Diabetes) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Type 1 Diabetes (Juvenile Diabetes), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Type 1 Diabetes (Juvenile Diabetes) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Type 1 Diabetes (Juvenile Diabetes)

The report reviews pipeline therapeutics for Type 1 Diabetes (Juvenile Diabetes) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Type 1 Diabetes (Juvenile Diabetes) therapeutics and enlists all their major and minor projects

The report assesses Type 1 Diabetes (Juvenile Diabetes) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Type 1 Diabetes (Juvenile Diabetes)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Type 1 Diabetes (Juvenile Diabetes)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Type 1 Diabetes (Juvenile Diabetes) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Adocia SAS

AiCuris GmbH & Co KG

Amarantus Bioscience Holdings Inc

Amarna Therapeutics BV

AntriaBio Inc

apceth Biopharma GmbH

Aphios Corp

Araim Pharmaceuticals Inc

Arecor Ltd

Astellas Pharma Inc

AstraZeneca Plc

Athersys Inc

Atlantic Bio Sci LLC

Axxam SpA

Beta-Cell NV

Biocon Ltd

BioLineRx Ltd

BioLingus AG

Biozeus

BirchBioMed Inc

Boehringer Ingelheim GmbH

BTB Pharma AB

Caladrius Biosciences Inc

Cancer Prevention Pharmaceuticals Inc

Compugen Ltd

Daewoong Pharmaceutical Co Ltd

Dance Biopharm Inc

DanDrit Biotech A/S

Denceptor Therapeutics Ltd

Diabetology (Products) Ltd

Diamyd Medical AB

Diasome Pharmaceuticals Inc

DiaVacs Inc

Dompe Farmaceutici SpA

Eli Lilly and Co

Ensol Biosciences Inc

EpiVax Inc

Escape Therapeutics Inc

Evotec AG

Fate Therapeutics Inc

GeNeuro SA

GenKyoTex SA

Geropharm LLC

GlaxoSmithKline Plc

Hanmi Pharmaceuticals Co Ltd

ImmusanT Inc

Intrexon Corp

Ixchel Pharma LLC

Johnson & Johnson

Just Biotherapeutics Inc

Kadimastem Ltd

Kamada Ltd

Kasiak Research Pvt Ltd

KPI Therapeutics Inc

Lexicon Pharmaceuticals Inc

Ligand Pharmaceuticals Inc

MacroGenics Inc

MannKind Corp

Maruho Co Ltd

Medestea Research & Production SpA

MedImmune LLC

Medtronic Plc

Medy-Tox Inc

Melior Discovery Inc

Merck & Co Inc

Meridigen Biotech Co Ltd

Mitsubishi Tanabe Pharma Corp

Neovacs SA

Novo Nordisk AS

Oramed Pharmaceuticals Inc

Orgenesis Inc

OSE Immunotherapeutics

Paras Biopharmaceuticals Finland Oy

Parvus Therapeutics Inc

Pathfinder Cell Therapy Inc

Pfizer Inc

PharmaCyte Biotech Inc

PharmaIN Corp

Prometheon Pharma LLC

Purzer Pharmaceutical Co Ltd

RedHill Biopharma Ltd

REGiMMUNE Corp

reMYND NV

Renova Therapeutics Inc

Rubius Therapeutics Inc

Sanofi

Semma Therapeutics Inc

Sevion Therapeutics Inc

Sotio AS

Tetragenetics Inc

Thermalin Diabetes LLC

Toleranzia AB

Topas Therapeutics GmbH

Transgene Biotek Ltd

Traverse Biosciences Inc

UCB SA

Unicyte AG

ViaCyte Inc

vTv Therapeutics Inc

XERIS Pharmaceuticals Inc

XL-protein GmbH

Zealand Pharma AS

Table of Contents

Table of Contents

Table of Contents 2

Introduction 7

Type 1 Diabetes (Juvenile Diabetes) - Overview 8

Type 1 Diabetes (Juvenile Diabetes) - Therapeutics Development 9

Type 1 Diabetes (Juvenile Diabetes) - Therapeutics Assessment 38

Type 1 Diabetes (Juvenile Diabetes) - Companies Involved in Therapeutics Development 50

Type 1 Diabetes (Juvenile Diabetes) - Drug Profiles 94

Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects 549

Type 1 Diabetes (Juvenile Diabetes) - Discontinued Products 558

Type 1 Diabetes (Juvenile Diabetes) - Product Development Milestones 560

Appendix 569

List of Tables

List of Tables

Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes), H2 2017 34

Number of Products under Development by Companies, H2 2017 36

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 37

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 38

Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017 39

Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017 40

Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017 41

Number of Products under Development by Companies, H2 2017 (Contd..6), H2 2017 42

Number of Products under Development by Companies, H2 2017 (Contd..7), H2 2017 43

Number of Products under Development by Universities/Institutes, H2 2017 44

Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 46

Number of Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017 47

Products under Development by Companies, H2 2017 48

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 49

Products under Development by Companies, H2 2017 (Contd..2), H2 2017 50

Products under Development by Companies, H2 2017 (Contd..3), H2 2017 51

Products under Development by Companies, H2 2017 (Contd..4), H2 2017 52

Products under Development by Companies, H2 2017 (Contd..5), H2 2017 53

Products under Development by Companies, H2 2017 (Contd..6), H2 2017 54

Products under Development by Companies, H2 2017 (Contd..7), H2 2017 55

Products under Development by Companies, H2 2017 (Contd..8), H2 2017 56

Products under Development by Companies, H2 2017 (Contd..9), H2 2017 57

Products under Development by Companies, H2 2017 (Contd..10), H2 2017 58

Products under Development by Companies, H2 2017 (Contd..11), H2 2017 59

Products under Development by Universities/Institutes, H2 2017 60

Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 61

Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017 62

Number of Products by Stage and Target, H2 2017 64

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 65

Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017 66

Number of Products by Stage and Mechanism of Action, H2 2017 68

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 69

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017 70

Number of Products by Stage and Route of Administration, H2 2017 72

Number of Products by Stage and Molecule Type, H2 2017 74

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Adocia SAS, H2 2017 75

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by AiCuris GmbH & Co KG, H2 2017 75

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Amarantus Bioscience Holdings Inc, H2 2017 76

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Amarna Therapeutics BV, H2 2017 76

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by AntriaBio Inc, H2 2017 77

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by apceth Biopharma GmbH, H2 2017 77

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Aphios Corp, H2 2017 77

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Araim Pharmaceuticals Inc, H2 2017 78

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Arecor Ltd, H2 2017 78

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Astellas Pharma Inc, H2 2017 79

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by AstraZeneca Plc, H2 2017 79

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Athersys Inc, H2 2017 80

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Atlantic Bio Sci LLC, H2 2017 80

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Axxam SpA, H2 2017 80

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Beta-Cell NV, H2 2017 81

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Biocon Ltd, H2 2017 81

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by BioLineRx Ltd, H2 2017 82

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by BioLingus AG, H2 2017 82

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Biozeus, H2 2017 83

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by BirchBioMed Inc, H2 2017 83

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Boehringer Ingelheim GmbH, H2 2017 83

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by BTB Pharma AB, H2 2017 84

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Caladrius Biosciences Inc, H2 2017 84

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Cancer Prevention Pharmaceuticals Inc, H2 2017 85

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Compugen Ltd, H2 2017 85

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2017 86

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Dance Biopharm Inc, H2 2017 86

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by DanDrit Biotech A/S, H2 2017 86

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Denceptor Therapeutics Ltd, H2 2017 87

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Diabetology (Products) Ltd, H2 2017 87

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Diamyd Medical AB, H2 2017 88

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Diasome Pharmaceuticals Inc, H2 2017 88

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by DiaVacs Inc, H2 2017 88

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Dompe Farmaceutici SpA, H2 2017 89

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Eli Lilly and Co, H2 2017 89

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Ensol Biosciences Inc, H2 2017 90

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by EpiVax Inc, H2 2017 90

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Escape Therapeutics Inc, H2 2017 90

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Evotec AG, H2 2017 91

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Fate Therapeutics Inc, H2 2017 92

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by GeNeuro SA, H2 2017 92

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by GenKyoTex SA, H2 2017 92

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Geropharm LLC, H2 2017 93

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by GlaxoSmithKline Plc, H2 2017 93

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017 94

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by ImmusanT Inc, H2 2017 94

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Intrexon Corp, H2 2017 95

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Ixchel Pharma LLC, H2 2017 95

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Johnson & Johnson, H2 2017 96

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Just Biotherapeutics Inc, H2 2017 96

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Kadimastem Ltd, H2 2017 97

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Kamada Ltd, H2 2017 97

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Kasiak Research Pvt Ltd, H2 2017 98

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by KPI Therapeutics Inc, H2 2017 98

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Lexicon Pharmaceuticals Inc, H2 2017 98

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Ligand Pharmaceuticals Inc, H2 2017 99

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by MacroGenics Inc, H2 2017 99

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by MannKind Corp, H2 2017 100

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Maruho Co Ltd, H2 2017 100

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Medestea Research & Production SpA, H2 2017 101

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by MedImmune LLC, H2 2017 101

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Medtronic Plc, H2 2017 101

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Medy-Tox Inc, H2 2017 102

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Melior Discovery Inc, H2 2017 102

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Merck & Co Inc, H2 2017 103

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Meridigen Biotech Co Ltd, H2 2017 103

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2017 104

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Neovacs SA, H2 2017 104

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Novo Nordisk AS, H2 2017 105

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Oramed Pharmaceuticals Inc, H2 2017 105

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Orgenesis Inc, H2 2017 106

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by OSE Immunotherapeutics, H2 2017 106

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Paras Biopharmaceuticals Finland Oy, H2 2017 107

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Parvus Therapeutics Inc, H2 2017 107

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Pathfinder Cell Therapy Inc, H2 2017 107

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Pfizer Inc, H2 2017 108

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by PharmaCyte Biotech Inc, H2 2017 108

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by PharmaIN Corp, H2 2017 109

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Prometheon Pharma LLC, H2 2017 109

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Purzer Pharmaceutical Co Ltd, H2 2017 109

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by RedHill Biopharma Ltd, H2 2017 110

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by REGiMMUNE Corp, H2 2017 110

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by reMYND NV, H2 2017 111

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Renova Therapeutics Inc, H2 2017 111

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Rubius Therapeutics Inc, H2 2017 111

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Sanofi, H2 2017 112

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Semma Therapeutics Inc, H2 2017 112

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Sevion Therapeutics Inc, H2 2017 113

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Sotio AS, H2 2017 113

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Tetragenetics Inc, H2 2017 113

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Thermalin Diabetes LLC, H2 2017 114

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Toleranzia AB, H2 2017 114

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Topas Therapeutics GmbH, H2 2017 115

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Transgene Biotek Ltd, H2 2017 115

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Traverse Biosciences Inc, H2 2017 115

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by UCB SA, H2 2017 116

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Unicyte AG, H2 2017 116

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by ViaCyte Inc, H2 2017 117

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by vTv Therapeutics Inc, H2 2017 117

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by XERIS Pharmaceuticals Inc, H2 2017 118

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by XL-protein GmbH, H2 2017 118

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Zealand Pharma AS, H2 2017 118

Type 1 Diabetes (Juvenile Diabetes) – Dormant Projects, H2 2017 574

Type 1 Diabetes (Juvenile Diabetes) – Dormant Projects, H2 2017 (Contd..1), H2 2017 575

Type 1 Diabetes (Juvenile Diabetes) – Dormant Projects, H2 2017 (Contd..2), H2 2017 576

Type 1 Diabetes (Juvenile Diabetes) – Dormant Projects, H2 2017 (Contd..3), H2 2017 577

Type 1 Diabetes (Juvenile Diabetes) – Dormant Projects, H2 2017 (Contd..4), H2 2017 578

Type 1 Diabetes (Juvenile Diabetes) – Dormant Projects, H2 2017 (Contd..5), H2 2017 579

Type 1 Diabetes (Juvenile Diabetes) – Dormant Projects, H2 2017 (Contd..6), H2 2017 580

Type 1 Diabetes (Juvenile Diabetes) – Dormant Projects, H2 2017 (Contd..7), H2 2017 581

Type 1 Diabetes (Juvenile Diabetes) – Dormant Projects, H2 2017 (Contd..8), H2 2017 582

Type 1 Diabetes (Juvenile Diabetes) – Discontinued Products, H2 2017 583

Type 1 Diabetes (Juvenile Diabetes) – Discontinued Products, H2 2017 (Contd..1), H2 2017 584

List of Figures

List of Figures

Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes), H2 2017 34

Number of Products under Development by Companies, H2 2017 35

Number of Products under Development by Universities/Institutes, H2 2017 44

Number of Products by Top 10 Targets, H2 2017 63

Number of Products by Stage and Top 10 Targets, H2 2017 63

Number of Products by Top 10 Mechanism of Actions, H2 2017 67

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 67

Number of Products by Top 10 Routes of Administration, H2 2017 71

Number of Products by Stage and Top 10 Routes of Administration, H2 2017 71

Number of Products by Top 10 Molecule Types, H2 2017 73

Number of Products by Stage and Top 10 Molecule Types, H2 2017 73

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports